Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine

Tsang Lau, Jawad AhmadDivision of Liver Diseases, Mount Sinai School of Medicine, New York, USAAbstract: The Model for End-Stage Liver Disease (MELD) score incorporates serum bilirubin, creatinine, and the international normalized ratio (INR) into a formula that provides a continuous variable that i...

Full description

Bibliographic Details
Main Authors: Lau T, Ahmad J
Format: Article
Language:English
Published: Dove Medical Press 2013-02-01
Series:Hepatic Medicine : Evidence and Research
Online Access:http://www.dovepress.com/clinical-applications-of-the-model-for-end-stage-liver-disease-meld-in-a12174
id doaj-c415818656d44382b482834626c1adba
record_format Article
spelling doaj-c415818656d44382b482834626c1adba2020-11-24T22:04:05ZengDove Medical PressHepatic Medicine : Evidence and Research1179-15352013-02-012013default110Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicineLau TAhmad JTsang Lau, Jawad AhmadDivision of Liver Diseases, Mount Sinai School of Medicine, New York, USAAbstract: The Model for End-Stage Liver Disease (MELD) score incorporates serum bilirubin, creatinine, and the international normalized ratio (INR) into a formula that provides a continuous variable that is a very accurate predictor of 90-day mortality in patients with cirrhosis. It is currently utilized in the United States to prioritize deceased donor organ allocation for patients listed for liver transplantation. The MELD score is superior to other prognostic models in patients with end-stage liver disease, such as the Child–Turcotte–Pugh score, since it uses only objective criteria, and its implementation in 2002 led to a sharp reduction in the number of people waiting for liver transplant and reduced mortality on the waiting list without affecting posttransplant survival. Although mainly adopted for use in patients waiting for liver transplant, the MELD score has also proved to be an effective predictor of outcome in other situations, such as patients with cirrhosis going for surgery and patients with fulminant hepatic failure or alcoholic hepatitis. Several variations of the original MELD score, involving the addition of serum sodium or looking at the change in MELD over time, have been examined, and these may slightly improve its accuracy. The MELD score does have limitations in situations where the INR or creatinine may be elevated due to reasons other than liver disease, and its implementation for organ allocation purposes does not take into consideration several conditions that benefit from liver transplantation. The application of the MELD score in prioritizing patients for liver transplantation has been successful, but further studies and legislation are required to ensure a fair and equitable system.Keywords: MELD score, liver transplantationhttp://www.dovepress.com/clinical-applications-of-the-model-for-end-stage-liver-disease-meld-in-a12174
collection DOAJ
language English
format Article
sources DOAJ
author Lau T
Ahmad J
spellingShingle Lau T
Ahmad J
Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
Hepatic Medicine : Evidence and Research
author_facet Lau T
Ahmad J
author_sort Lau T
title Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
title_short Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
title_full Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
title_fullStr Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
title_full_unstemmed Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
title_sort clinical applications of the model for end-stage liver disease (meld) in hepatic medicine
publisher Dove Medical Press
series Hepatic Medicine : Evidence and Research
issn 1179-1535
publishDate 2013-02-01
description Tsang Lau, Jawad AhmadDivision of Liver Diseases, Mount Sinai School of Medicine, New York, USAAbstract: The Model for End-Stage Liver Disease (MELD) score incorporates serum bilirubin, creatinine, and the international normalized ratio (INR) into a formula that provides a continuous variable that is a very accurate predictor of 90-day mortality in patients with cirrhosis. It is currently utilized in the United States to prioritize deceased donor organ allocation for patients listed for liver transplantation. The MELD score is superior to other prognostic models in patients with end-stage liver disease, such as the Child–Turcotte–Pugh score, since it uses only objective criteria, and its implementation in 2002 led to a sharp reduction in the number of people waiting for liver transplant and reduced mortality on the waiting list without affecting posttransplant survival. Although mainly adopted for use in patients waiting for liver transplant, the MELD score has also proved to be an effective predictor of outcome in other situations, such as patients with cirrhosis going for surgery and patients with fulminant hepatic failure or alcoholic hepatitis. Several variations of the original MELD score, involving the addition of serum sodium or looking at the change in MELD over time, have been examined, and these may slightly improve its accuracy. The MELD score does have limitations in situations where the INR or creatinine may be elevated due to reasons other than liver disease, and its implementation for organ allocation purposes does not take into consideration several conditions that benefit from liver transplantation. The application of the MELD score in prioritizing patients for liver transplantation has been successful, but further studies and legislation are required to ensure a fair and equitable system.Keywords: MELD score, liver transplantation
url http://www.dovepress.com/clinical-applications-of-the-model-for-end-stage-liver-disease-meld-in-a12174
work_keys_str_mv AT laut clinicalapplicationsofthemodelforendstageliverdiseasemeldinhepaticmedicine
AT ahmadj clinicalapplicationsofthemodelforendstageliverdiseasemeldinhepaticmedicine
_version_ 1725830549805727744